Advice
following a full submission
tiotropium (Spiriva® Respimat®) is accepted for use within NHS Scotland.
Indication under review: As add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 micrograms budesonide/day or equivalent) and long-acting beta2 agonists and who experienced one or more severe exacerbations in the previous year.
Two phase III RCTs demonstrated that the addition of tiotropium significantly improved lung function and increased the time to the first severe exacerbation compared with placebo in patients with uncontrolled asthma despite treatment with high dose inhaled corticosteroid and a long acting beta2 agonist.
Download detailed advice323KB (PDF)
Medicine details
- Medicine name:
- tiotropium, 2.5 microgram, solution for inhalation (Spiriva® Respimat®)
- SMC ID:
- 1028/15
- Indication:
- As add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 micrograms budesonide/day or equivalent) and long-acting beta2 agonists and who experienced one or more severe exacerbations in the previous year.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 August 2015